Page last updated: 2024-08-24

mibefradil and ketoconazole

mibefradil has been researched along with ketoconazole in 14 studies

Research

Studies (14)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (7.14)18.2507
2000's6 (42.86)29.6817
2010's6 (42.86)24.3611
2020's1 (7.14)2.80

Authors

AuthorsStudies
Dantzig, AH; Ekins, S; Kim, RB; Lan, LB; Leake, BF; Schuetz, EG; Schuetz, JD; Shepard, RL; Wikel, JH; Winter, MA; Wrighton, SA; Yasuda, K1
Fischer, H; Huwyler, J; Poli, S; Schwab, D; Tabatabaei, A1
Keserü, GM1
Bacsó, Z; Cianfriglia, M; Fenyvesi, F; Goda, K; Kappelmayer, J; Lustyik, G; Nagy, H; Szabó, G; Szilasi, M1
Nagashima, R; Nishikawa, T; Tobita, M1
Jia, L; Sun, H1
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ1
Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ1
Ekins, S; Williams, AJ; Xu, JJ1
Cheon, SH; Choi, K; Hahn, HG; Han, M; Song, C; Yun, J1
Hahn, HG; Han, M; Jeong, N; Song, C1
Assang, C; Baillie, TA; Lin, JH; Lu, P; Ma, B; Meng, Y; Prueksaritanont, T; Reider, PJ; Tang, C1
Goto, T; Tohkin, M; Yamazoe, Y1
Byun, JS; Kim, HJ; Lee, JY; Lee, KT; Leem, DG; Nam, JH; Park, B; Shin, DH; Shin, JS; Sohn, JM1

Other Studies

14 other study(ies) available for mibefradil and ketoconazole

ArticleYear
Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein.
    Molecular pharmacology, 2002, Volume: 61, Issue:5

    Topics: Animals; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Caco-2 Cells; Ergonovine; Fluoxetine; Humans; Models, Molecular; Oxytocics; Protein Conformation; Selective Serotonin Reuptake Inhibitors; Structure-Activity Relationship; Swine; Transfection; Vinblastine

2002
Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.
    Journal of medicinal chemistry, 2003, Apr-24, Volume: 46, Issue:9

    Topics: Adenosine Triphosphatases; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Cells, Cultured; Drug Evaluation, Preclinical; Fluoresceins; Fluorescent Dyes; Humans; Indicators and Reagents; Mice; Models, Molecular; Rhodamines; Species Specificity; Swine

2003
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.
    Bioorganic & medicinal chemistry letters, 2003, Aug-18, Volume: 13, Issue:16

    Topics: Cation Transport Proteins; Databases, Factual; Discriminant Analysis; Ether-A-Go-Go Potassium Channels; Holography; Linear Models; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quantitative Structure-Activity Relationship

2003
Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies.
    Biochemical and biophysical research communications, 2004, Mar-19, Volume: 315, Issue:4

    Topics: Adenosine Triphosphatases; Animals; Anti-Bacterial Agents; Antibodies, Monoclonal; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Binding, Competitive; Calcium Channel Blockers; Cyclosporine; Detergents; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Flow Cytometry; Fluoresceins; Humans; Ivermectin; Mice; NIH 3T3 Cells; Substrate Specificity

2004
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.
    Bioorganic & medicinal chemistry letters, 2005, Jun-02, Volume: 15, Issue:11

    Topics: Animals; CHO Cells; Cricetinae; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Potassium Channel Blockers; Potassium Channels, Voltage-Gated

2005
Support vector machines classification of hERG liabilities based on atom types.
    Bioorganic & medicinal chemistry, 2008, Jun-01, Volume: 16, Issue:11

    Topics: Animals; Arrhythmias, Cardiac; CHO Cells; Computer Simulation; Cricetinae; Cricetulus; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Chemical; Patch-Clamp Techniques; Potassium Channel Blockers; Potassium Channels, Voltage-Gated; Predictive Value of Tests; ROC Curve

2008
Developing structure-activity relationships for the prediction of hepatotoxicity.
    Chemical research in toxicology, 2010, Jul-19, Volume: 23, Issue:7

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes

2010
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2010, Volume: 118, Issue:2

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics

2010
A predictive ligand-based Bayesian model for human drug-induced liver injury.
    Drug metabolism and disposition: the biological fate of chemicals, 2010, Volume: 38, Issue:12

    Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands

2010
Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.
    Bioorganic & medicinal chemistry letters, 2014, Aug-01, Volume: 24, Issue:15

    Topics: Azetidines; Biological Transport; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Ether-A-Go-Go Potassium Channels; Humans; Molecular Structure; Neurotransmitter Uptake Inhibitors; Phenyl Ethers; Plasma Membrane Neurotransmitter Transport Proteins; Serotonin; Structure-Activity Relationship

2014
Exploration of 3-Aminoazetidines as Triple Reuptake Inhibitors by Bioisosteric Modification of 3-α-Oxyazetidine.
    ACS medicinal chemistry letters, 2014, Sep-11, Volume: 5, Issue:9

    Topics:

2014
Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors: an in vitro investigation with human liver preparations.
    British journal of clinical pharmacology, 1999, Volume: 47, Issue:3

    Topics: Aryl Hydrocarbon Hydroxylases; Atorvastatin; Benzimidazoles; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Drug Interactions; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Ketoconazole; Kinetics; Lovastatin; Mibefradil; Microsomes, Liver; Oxidoreductases, N-Demethylating; Pyridines; Pyrroles; Simvastatin; Tetrahydronaphthalenes

1999
Versatile applicability of a grid-based CYP3A4 Template to understand the interacting mechanisms with the small-size ligands; part 3 of CYP3A4 Template study.
    Drug metabolism and pharmacokinetics, 2020, Volume: 35, Issue:3

    Topics: Coumarins; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Humans; Ketoconazole; Ligands; Mibefradil; Molecular Structure; Nicardipine

2020
In vitro synergistic anticancer activity of the combination of T-type calcium channel blocker and chemotherapeutic agent in A549 cells.
    Bioorganic & medicinal chemistry letters, 2016, Feb-01, Volume: 26, Issue:3

    Topics: Animals; Antineoplastic Agents; Apoptosis; Calcium Channel Blockers; Calcium Channels, T-Type; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p27; Cyclin-Dependent Kinases; Cyclins; Dogs; Down-Regulation; G1 Phase Cell Cycle Checkpoints; Half-Life; Humans; Mice; Microsomes, Liver; Quinazolines; Rats; Up-Regulation

2016